View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® Online CME Activity

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Reata Pharmaceuticals.


Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Release Date: April 28, 2017
Expiration Date: April 28, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® features a case-based discussion of current and developing therapies for patients with melanoma and Merkel cell carcinoma, including targeted therapy and immune checkpoint inhibitors. Interactive clinical vignettes are followed by short video interviews with leading experts in cutaneous malignancies and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians engaged in the care of patients with cutaneous malignancies.

CME/CE Activity Table of Contents

  • Module 1. Metastatic Melanoma (BRAF-Mutation Positive)
  • Module 2. Metastatic Melanoma (BRAF-wild type)
  • Module 3. Advanced Merkel Cell Carcinoma

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Choose treatment based on patient characteristics, such as age and performance status.
  • Assess the roles of regional therapies, targeted therapies, and immunotherapies in the treatment of patients.
  • Review strategies for mitigating and managing adverse events related to therapy.
  • Describe current and emerging strategies for individualizing therapy.
  • Evaluate emerging clinical data regarding new regional therapies, targeted therapies, and immunotherapies in treating melanoma and other cutaneous malignancies.

Faculty, Staff, and Planners' Disclosures

Faculty

Jeffrey Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Disclosure: Grant Support Research: Bristol-Myers Squibb (BMS), GlaxoSmithKline plc (GSK), Merck, Incyte, Genentech all to Moffitt; Consultant: BMS, GSK, Merck, Incyte, Genentech, AstraZeneca, Medivation; Shareholder: Altor, Celldex Therapeutics, cCAM Medical Ltd., CytomX Therapeutics; Other: named on a patent held by Moffitt that relates to a predictive marker for ipilimumab.

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Disclosure: Grant Support Research: AstraZeneca, Bristol-Myers Squibb (BMS), Celldex Therapeutics, Genentech, Immunocore, Incyte, Merck, Merck Serono, MedImmune, Novartis, Pfizer, Rinat, Roche; Consultant: Amgen, Novartis, Roche, BMS, Merck; Shareholder: BMS, Genentech, Novartis, Amgen

Michael Postow, MD
Assistant Attending Physician
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Grant Support Research: Bristol-Myers Squibb (BMS); Consultant: BMS, Amgen, Novartis

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

 

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By